Today’s Stocks : Acasti Pharma Inc. (NASDAQ:ACST), OvaScience, Inc. (NASDAQ:OVAS), Jack Henry & Associates Inc. (NASDAQ:JKHY), InvenSense, Inc. (NYSE:INVN), Facebook Inc (NASDAQ:FB)

On Sep 30, Acasti Pharma Inc. (NASDAQ:ACST), announces top-line results for its pharmacokinetic (PK) trial evaluating the bioavailability and safety of CaPre® on healthy individuals taking single and multiple daily oral doses of the Corporation’s new investigational drug candidate composed of a patent-protected highly concentrated novel omega-3 phospholipid for the prevention and treatment of certain cardiometabolic disorders. Acasti Pharma Inc. (NASDAQ:ACST) belongs to Healthcare sector. Its weekly performance is -33.16%. On last trading day company shares ended up $0.65. Acasti Pharma Inc. (NASDAQ:ACST) distance from 50-day simple moving average (SMA50) is -31.50%.

OvaScienceSM (NASDAQ: OVAS), announced the appointment of Jeffrey Young to Chief Financial Officer. Mr. Young joins OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions. OvaScience, Inc. (NASDAQ:OVAS) shares decreased -1.44% in last trading session and ended the day at $16.43. OVAS return on assets is -51.40%. OvaScience, Inc. (NASDAQ:OVAS) quarterly performance is 76.10%.

Jack Henry & Associates (NASDAQ:JKHY) VP Mark S. Forbis sold 4,500 shares of the company’s stock on the open market in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $57.54, for a total value of $258,930.00. Following the sale, the vice president now directly owns 4,854 shares in the company, valued at approximately $279,299. On 03 October, Jack Henry & Associates Inc. (NASDAQ:JKHY) shares moved up 0.83% and was closed at $56.19. JKHY EPS growth in last 5 year was 14.10%. Jack Henry & Associates Inc. (NASDAQ:JKHY) year to date (YTD) performance is -4.01%.

InvenSense (NASDAQ:INVN) has received an average rating of “Buy” from the fifteen analysts that are currently covering the company, reports. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. InvenSense, Inc. (NYSE:INVN) ended the last trading day at $20.68. Company weekly volatility is calculated as 5.32% and price to cash ratio as 12.55. InvenSense, Inc. (NYSE:INVN) showed a weekly performance of 3.76%.

The European Commission has Friday approved the proposed acquisition of mobile messaging start-up WhatsApp, Inc. by Social networking giant Facebook Inc (NASDAQ:FB), both based in the U.S. The deal was notified to the Commission on August 29, 2014. Facebook agreed in mid-February to acquire WhatsApp in a cash and stock deal valued at about $19 billion, including $3 billion in restricted stock units to be granted to WhatsApp’s founders and employees over four years. WhatsApp is Facebook’s biggest acquisition by far. Facebook Inc (NASDAQ:FB) belongs to Technology sector. Its net profit margin is 23.70% and weekly performance is -1.71%. On last trading day company shares ended up $77.44. Facebook Inc (NASDAQ:FB) distance from 50-day simple moving average (SMA50) is 2.55%.